The science minister Chris McDonald has said the government's drive to commercialise NHS patient data will continue under Andy Burnham, telling the Financial Times' Global Pharma and Biotech Summit that the UK should "exploit" its health records to attract pharmaceutical investment and power AI-led drug discovery, the FT has reported.
McDonald, who holds a joint ministerial post in the business and health departments, said the UK uniquely holds a large longitudinal health dataset that cannot be replicated elsewhere, giving it a "strategic competitive advantage" when combined with an AI industry he described as at least the third best in the world.
He said he wanted to ensure "NHS data becomes a very powerful driver for investment", and that the policy begun under Sir Keir Starmer, which the FT noted caused consternation among some Labour MPs, would not change under the new Prime Minister.
The minister acknowledged that the strategy rested on public trust. He told the summit he was "very aware" that the government's life sciences ambitions depended on the trust and confidence placed in the NHS brand, and that the data could only be exploited if that trust was maintained. The FT reports that his remarks came amid concern about Palantir's role in the NHS and the offering for sale of UK Biobank participant data following a security breach.
McDonald did not engage with the view, held by some in government according to the newspaper, that easing Palantir out is necessary to maintain voter trust, instead emphasising "governance and assurance" and pointing to ministerial pressure on UK Biobank to suspend access after the incident. The FT reported last week that Palantir's NHS contract is to be extended for two years while a fresh procurement is run with greater emphasis on UK technology sovereignty.
Patient data held by the NHS is confidential and its use for purposes beyond direct care is governed by the common law duty of confidentiality, the UK GDPR and Data Protection Act 2018, the Caldicott principles and the National Data Guardian's oversight, with the national data opt-out allowing patients to object to their confidential information being used for research and planning.
The Data (Use and Access) Act 2025 introduced information standards for health and care IT suppliers and a framework for recognised legitimate interests, but did not alter the confidentiality basis on which NHS data is shared with commercial users. None of this was referenced in the minister's remarks as reported.
The FT's report is at https://www.ft.com/content/f95d9298-d27e-4c1b-87e5-ea75f67a1e0c (subscription required).
